See more : noco-noco Inc. (NCNC) Income Statement Analysis – Financial Results
Complete financial analysis of Biocept, Inc. (BIOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biocept, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Dynagreen Environmental Protection Group Co., Ltd. (601330.SS) Income Statement Analysis – Financial Results
- Jainex Aamcol Limited (JAINEX.BO) Income Statement Analysis – Financial Results
- Metalart Corporation (5644.T) Income Statement Analysis – Financial Results
- Pan African Resources PLC (PAF.L) Income Statement Analysis – Financial Results
- Guangzhou Lingnan Group Holdings Company Limited (000524.SZ) Income Statement Analysis – Financial Results
Biocept, Inc. (BIOC)
About Biocept, Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.86M | 61.25M | 27.46M | 5.53M | 3.25M | 5.07M | 3.22M | 609.91K | 133.42K | 134.25K | 109.29K | 1.05K |
| Cost of Revenue | 28.44M | 37.76M | 21.34M | 10.98M | 10.05M | 9.35M | 6.92M | 4.60M | 2.17M | 2.33M | 1.20M | 17.32K |
| Gross Profit | -2.58M | 23.49M | 6.12M | -5.45M | -6.80M | -4.28M | -3.70M | -3.99M | -2.04M | -2.20M | -1.09M | -16.27K |
| Gross Profit Ratio | -9.99% | 38.34% | 22.30% | -98.56% | -209.26% | -84.37% | -114.70% | -653.58% | -1,526.91% | -1,635.56% | -999.56% | -1,546.58% |
| Research & Development | 6.16M | 4.96M | 5.22M | 4.70M | 4.47M | 3.36M | 2.71M | 2.86M | 4.50M | 3.09M | 6.56M | 8.85M |
| General & Administrative | 16.11M | 12.61M | 9.97M | 6.97M | 7.07M | 7.19M | 6.56M | 5.69M | 5.20M | 2.51M | 2.06M | 2.73M |
| Selling & Marketing | 7.13M | 8.32M | 6.40M | 5.94M | 5.91M | 6.34M | 5.05M | 3.88M | 2.14M | 148.90K | 785.32K | 672.93K |
| SG&A | 23.24M | 20.93M | 16.37M | 12.91M | 12.99M | 13.53M | 11.61M | 9.57M | 7.34M | 2.66M | 2.85M | 3.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.40M | 25.89M | 21.59M | 17.61M | 17.46M | 16.90M | 14.33M | 12.42M | 11.84M | 5.75M | 9.41M | 12.25M |
| Cost & Expenses | 57.84M | 63.66M | 42.93M | 28.59M | 27.51M | 26.24M | 21.25M | 17.02M | 14.01M | 8.08M | 10.61M | 12.27M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 316.00K | 290.00K | 2.34M | 2.08M | 310.98K | 0.00 | 0.00 | 0.00 | 0.00 | 2.07M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.66M | 2.64M | 1.00M | 773.31K | 800.91K | 575.72K | 322.03K | 261.41K | 251.20K | 266.55K | 365.57K | 369.31K |
| EBITDA | -30.33M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.68M | -10.57M | -12.24M |
| EBITDA Ratio | -117.29% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,719.30% | -9,671.01% | -1,163,859.41% |
| Operating Income | -31.98M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.94M | -10.50M | -12.27M |
| Operating Income Ratio | -123.69% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,917.86% | -9,610.37% | -1,166,444.49% |
| Total Other Income/Expenses | -229.00K | -290.00K | -2.34M | -2.08M | -310.98K | -431.41K | -372.23K | -537.12K | -1.99M | -1.29M | -1.76M | -1.36M |
| Income Before Tax | -32.21M | -2.70M | -17.81M | -25.14M | -24.57M | -21.61M | -18.40M | -16.95M | -15.86M | -9.23M | -12.26M | -13.63M |
| Income Before Tax Ratio | -124.57% | -4.41% | -64.84% | -454.69% | -755.92% | -426.27% | -570.79% | -2,778.76% | -11,891.12% | -6,877.26% | -11,216.80% | -1,295,483.46% |
| Income Tax Expense | -125.00K | 125.00K | -764.58K | -523.33K | 1.89K | 7.62K | 2.05K | 1.61K | 1.51K | 800.00 | 800.00 | 800.00 |
| Net Income | -32.09M | -2.82M | -17.04M | -24.61M | -24.57M | -21.61M | -18.40M | -16.95M | -15.87M | -9.23M | -12.26M | -13.63M |
| Net Income Ratio | -124.09% | -4.61% | -62.06% | -445.23% | -755.98% | -426.42% | -570.86% | -2,779.03% | -11,892.25% | -6,877.86% | -11,217.53% | -1,295,559.51% |
| EPS | -56.78 | -5.73 | -43.16 | -357.54 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| EPS Diluted | -56.78 | -5.73 | -43.16 | -357.41 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| Weighted Avg Shares Out | 565.13K | 492.53K | 394.84K | 68.85K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
| Weighted Avg Shares Out (Dil) | 565.13K | 492.53K | 394.84K | 68.87K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
Biocept Reports First Quarter 2023 Financial Results
Biocept Reports First Quarter 2023 Financial Results
Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year
Biocept Reports 2022 Financial Results
Biocept Reports 2022 Financial Results
Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastases
Enrollment Begins in FORESEE Clinical Trial Using Biocept's CNSide™ to Evaluate Patients with Leptomeningeal Metastases
Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports